Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Docetaxel

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Roche - Basel

Roche re-joins UK pharma’s trade body the ABPI

Firm left in 2009 following its suspension for a major Code of Practice breach 

- PMLiVE

Boehringer to add wireless data-collection to its Respimat inhaler

Joins forces with Qualcomm for COPD adherence collaboration

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

Roche Basel Switzerland

Roche says Tecentriq “off to a good start”

Bladder cancer therapy drug seems set for rapid growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links